IBJNews

Lilly: Forget Alzheimer's; think diabetes

Back to TopCommentsE-mailPrintBookmark and Share

For more than a year, Eli Lilly and Co. has been viewed by investors as a laggard stock with one, slim shot at producing a huge jackpot: its experimental Alzheimer’s drug. But now company leaders are trying to direct investor attention toward what they view as a sure-fire bet: the drugmaker’s diabetes portfolio.

Lilly brass spent significant time during an investor conference call last month talking up their diabetes pipeline. Then last week they scheduled a special 90-minute call on June 11 that will be devoted to nothing but the diabetes pipeline.

There’s good reason for this. Some analysts put the chances of success of solanezumab, Lilly’s experimental Alzheimer’s medicine, at 10 percent or less. If it succeeds, the drug could generate $10 billion in annual sales and negate challenges posed by the string of patent loses on blockbuster drugs through which Lilly is suffering.

But diabetes has a 100-percent chance of bringing Lilly significantly more revenue over the next few years, as the incidence of the chronic disease rises sharply across the globe. That will help Lilly sell more of its insulins and its latest product, called Tradjenta.

Most analysts expect Lilly’s diabetes sales to grow more than 30 percent over the next four years—even before any new drugs coming out of its pipeline. That would mean an additional $1.3 billion in annual revenue.

And if the pipeline starts producing winners, the potential is even greater.

“LLY has one of the most attractive diabetes portfolios amongst its peer group,” Barclays Capital analyst Tony Butler wrote in an April 25 research note, referring to Lilly by its ticker symbol. “While there are inherent risks in all clinical programs, we believe diabetes could be an area that offers a lower risk profile as compared to that of Alzheimer’s or oncology.”

What’s in Lilly’s diabetes pipeline? A drug called empagliflozin is designed to boost glucose re-absorption in patients' kidneys, thus reducing levels of glucose in their blood.

Another drug is a glucagon-like peptide called dulaglutide, which Lilly thinks so highly of that it sold off its rights to the pioneer of this class of drugs, Byetta, which it launched in 2005 along with the drug’s creator, California-based Amylin Pharmaceuticals Inc.

Also, Lilly is developing two once-daily basal insulins—which if approved could finally stem the losses Lilly has suffered since the 2000 launch of the first basal insulin, Lantus.

“So I think all of this augurs well for us being able to offer a broad range of products to the dietologist, to the physician to really focus on what the patient needs and not just on what we have to offer,” Lilly CEO John Lechleiter said during the April 25 conference call.

Lilly is admittedly trying to play catch up to Denmark-based Novo Nordisk A/S and France-based Sanofi-Aventis SA in the diabetes business. In 1923, Lilly was the global pioneer of insulin. But its diabetes sales in recent years have grown half as fast as the overall global market.
 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. What became of this project? Anyone know?

  2. Scott, could you post an enlarged photo of the exterior of the building? This will be a great addition to Walnut Street. This area will only continue to develop with additions like this. Also, please give us more updates on the "Cultural Trail light" expansion. Also a great move for the city, as long as there is maintenance money set aside.

  3. Great story IBJ! Citizens don't have a real sense of the financial magnitude of supporting Indy's sports and tourism sector. The CIB was a brilliant idea for creating a highly integrated public-private partnership to support this sector from the economic activity it generates. Unfortunately, most folks think the benefits of that economic activity accrue directly to the City budget, and it doesn't. So though the CIB is facing lean times (covering its costs while maintaining minimally acceptable reserves), the City is operating with deficit - less tax revenue than expenses each year - with a very fragile reserve balance. That's why it's so challenging for the City to fund basic needs or new intitatives (e.g. pre-k education; new jail), and some credit rating agencies have downgraded Indy from it's past stellar AAA status. More reporting on City finances would be welcomed.

  4. Sure, I'll admit that it bugs me to see that the IBJ.COM censors it's blog posts almost as much as the D of I does when someone points out the falsehoods and fabrications. _____But I think it bothers me almost as much that Captain/Defender/Disciple get his yanked too. You see, those of us with a sense of integrity, humanity, compassion, and a need for fact based opinion WANT to see all of his screeds posted. It makes our point so much better than we can do it ourselves.

  5. We're conflating two very different topics. Voter fraud is a myth and excessive gun violence is all too real. I just hope rational gunowners decide to stop being shouted down by the, well, let's call them "less rational" ones.

ADVERTISEMENT